SCHEMBL8203917

SCHEMBL8203917

COc1cc2c(cc1OC)C(CCc1ccc(C)cc1)N(C)CC2

nearest known ligand 0.80

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ NR1I2 O75469 1/20 0.80
▸ MAOA P21397 1/20 0.80
▸ PTGS2 P35354 1/20 0.80
▸ OPRK1 P41145 1/20 0.80
▸ SLC6A3 Q01959 1/20 0.80
▸ KCNN2 Q9H2S1 4/20 0.68
▸ KCNN3 Q9UGI6 4/20 0.68
▸ KCNN1 Q92952 2/20 0.68
▸ MAPK1 P28482 2/20 0.66
▸ LMNA P02545 2/20 0.66
▸ KDM4E B2RXH2 2/20 0.66
▸ ALDH1A1 P00352 2/20 0.66
▸ HSD17B10 Q99714 2/20 0.66
▸ TP53 P04637 1/20 0.66
▸ TSHR P16473 1/20 0.66
▸ CYP2D6 P10635 1/20 0.66
▸ ALOX15 P16050 1/20 0.62
▸ MTNR1B P49286 3/20 0.57
▸ KCNH2 Q12809 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methopholine SCHEMBL30492235 0.89 NR1I2 (1.00) NR1I2MAOAPTGS2OPRK1SLC6A3
Methopholine SCHEMBL26169 0.89 NR1I2 (1.00) NR1I2MAOAPTGS2OPRK1SLC6A3
SCHEMBL27961570 0.85 MAOA (0.72) NR1I2MAOAPTGS2OPRK1SLC6A3
SCHEMBL3250242 0.82 KCNN2 (1.00) NR1I2MAOAPTGS2OPRK1SLC6A3
SCHEMBL3253219 0.82 KCNN2 (0.94) NR1I2MAOAPTGS2OPRK1SLC6A3
Homolaudanosine SCHEMBL7550998 0.81 NR1I2 (0.67) NR1I2MAOAPTGS2OPRK1SLC6A3
SCHEMBL5908036 0.81 TP53 (0.98) NR1I2MAOAPTGS2OPRK1SLC6A3
SCHEMBL29651290 0.81 TP53 (0.98) NR1I2MAOAPTGS2OPRK1SLC6A3
SCHEMBL12021032 0.81 LMNA (0.70) MAPK1LMNAKDM4EALDH1A1HSD17B10
SCHEMBL3251892 0.80 KCNN2 (0.91) NR1I2MAOAPTGS2OPRK1SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5952344-A TREATING AND CONTROL OF DISEASES WHICH REPRESENT THERAPEUTIC INDICATIONS FOR NMDA(N-METHYL-D-ASPERTATE) RECEPTOR SUBTYPE SPECIFIC BLOKERS BY ADMINISTERING TETRAHYDROISOQUINOLINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 1999-09-14 — — US claimed
EP-0787493-A1 Tetrahydroisoquinoline derivatives F. HOFFMANN-LA ROCHE AG (CH) 1997-08-06 — — EP claimed
US-6071929-A SELECTIVE BLOCKERS OF N-METHYL-D-ASPARTIC ACID FOR TEATMENT OF NERVOUS SYSTEM AND BRAIN DISORDERS OR INJURIES HOFFMAN-LA ROCHE INC. (US) 2000-06-06 — — US disclosed
US-5952344-A TREATING AND CONTROL OF DISEASES WHICH REPRESENT THERAPEUTIC INDICATIONS FOR NMDA(N-METHYL-D-ASPERTATE) RECEPTOR SUBTYPE SPECIFIC BLOKERS BY ADMINISTERING TETRAHYDROISOQUINOLINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 1999-09-14 — — US disclosed
EP-0787493-A1 Tetrahydroisoquinoline derivatives F. HOFFMANN-LA ROCHE AG (CH) 1997-08-06 — — EP disclosed
Send feedback